Intervention not reported
Nausea/vomiting* grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher nausea/vomiting* grade 3 or 4 (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Nephrotoxicity (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Anaemia grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher anaemia grade 3 or 4 (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Hair loss (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to lower hair loss (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Leukopaenia (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention probably leads to higher leukopaenia (safety population) (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)
The intervention showed no clear difference in overall survival ‐ trials of metastatic breast cancer participants… (high certainty).
1 finding from 1 review
Intervention not reported
Leukopenia** grade 3 or 4 (safety population) · women with metastatic breast cancer
The intervention probably leads to higher leukopenia** grade 3 or 4 (safety population) (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival/time to progression (randomised participants) ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)
The intervention showed no clear difference in progression‐free survival/time to progression (randomised… (moderate certainty).
1 finding from 1 review
Intervention not reported
Objective tumour response rate (assessable participants) ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)
The intervention may leads to higher objective tumour response rate (assessable participants) ‐ trials of… (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention showed no clear difference in overall survival ‐ trials of mTNBC participants (low certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival/time to progression (randomised participants) ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to lower progression‐free survival/time to progression (randomised… (low certainty).
1 finding from 1 review
Intervention not reported
Objective tumour response rate (assessable participants) ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher objective tumour response rate (assessable participants) ‐ trials of… (low certainty).
1 finding from 1 review
Intervention not reported
Hair loss grade 3 or 4 (safety population) · women with metastatic breast cancer
The intervention leads to higher hair loss grade 3 or 4 (safety population) (high certainty).
1 finding from 1 review